Mustafa Yildiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mustafa Yildiz has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Aysel İnCedere
Department of Psychosocial Rehabilitation, Kocaeli University Institute of Health Science, Kocaeli, Turkey
8 shared publications - Sukriye Bosgelmez
Kocaeli Derince Training and Research Hospital
5 shared publications - Umit Tural
Clinical Research Division, The Nathan S. Kline Institute for Psychiatric Research, Orangeburg, USA
5 shared publications - Esra Yazici
Faculty of Medicine, Department of Psychiatry, Sakarya University, Sakarya, Turkey
4 shared publications - Fatma Kiras
Department of Psychiatry, Kocaeli University School of Medicine, Kocaeli, Turkey
4 shared publications Ayla Yazici
3 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by AVES YAYINCILIK A.Ş. in Neuropsychiatric Investigation
- Vol. 64, 1-8
Antipsychotic Treatment Patterns and Associated Clinical Characteristics in Schizophrenia: A Multicenter Study from Community Mental Health Centers in Türkiye
Objective: To describe antipsychotic treatment patterns among patients with schizophrenia receiving care at Community Mental Health Centers (CMHCs) in Türkiye and to examine associated clinical characteristics. Methods: In this multicenter, cross-sectional study, 181 clinically stable patients with schizophrenia receiving CMHC care were evaluated. Antipsychotic treatment patterns were categorized as antipsychotic monotherapy (APM) vs. antipsychotic polypharmacy (APP), oral vs. long-acting injectable antipsychotic (LAI) treatment, and second-generation antipsychotic (SGA) vs. first-generation antipsychotic (FGA). Symptom severity and clinical status were assessed with the mini-Positive and Negative Syndrome Scale (m-PANSS), Brief Clinical Assessment Scale for Schizophrenia (BCASS), Clinical Global Impression–Severity (CGI-S), Global Assessment of Functioning (GAF), and Global Assessment of Medication Adherence. Results: Antipsychotic polypharmacy was common (65.2%), and LAI use was high (60.2%; LAI alone 17.1%, oral + LAI 43.1%). Most patients received SGAs only (82.9%), whereas 17.1% used an FGA + SGA combination. Compared with APM, APP was associated with older age, longer illness duration, and more hospitalizations, as well as greater symptom burden and clinical severity (higher m-PANSS and BCASS scores and higher CGI-S) and poorer functioning (lower GAF). Clozapine was prescribed to 21.5% of patients, predominantly within APP. Conclusion: In patients with schizophrenia receiving care at CMHCs in Türkiye, prescription is characterized by frequent APP and substantial LAI use, concentrated among individuals with more severe and chronic illness profiles. These real-world patterns may diverge from guideline-recommended pathways and underscore the need for individualized, evidence-based strategies to optimize outcomes in CMHC populations. Cite this article as: Asan Ö, Yıldız M, Kenar ANİ, et al. Antipsychotic treatment patterns and associated clinical characteristics in schizophrenia: a multicenter study from community mental health centers in Türkiye. Neuropsychiatr Invest. 2026, 64, 0002, doi: 10.5152/NI.2026.26002.
- 22 June 2026
- Published by AVES YAYINCILIK A.Ş. in Neuropsychiatric Investigation
- Vol. 64, 1-8
Open AccessAntipsychotic Treatment Patterns and Associated Clinical Characteristics in Schizophrenia: A Multicenter Study from Community Mental Health Centers in Türkiye
Objective: To describe antipsychotic treatment patterns among patients with schizophrenia receiving care at Community Mental Health Centers (CMHCs) in Türkiye and to examine associated clinical characteristics. Methods: In this multicenter, cross-sectional study, 181 clinically stable patients with schizophrenia receiving CMHC care were evaluated. Antipsychotic treatment patterns were categorized as antipsychotic monotherapy (APM) vs. antipsychotic polypharmacy (APP), oral vs. long-acting injectable antipsychotic (LAI) treatment, and second-generation antipsychotic (SGA) vs. first-generation antipsychotic (FGA). Symptom severity and clinical status were assessed with the mini-Positive and Negative Syndrome Scale (m-PANSS), Brief Clinical Assessment Scale for Schizophrenia (BCASS), Clinical Global Impression–Severity (CGI-S), Global Assessment of Functioning (GAF), and Global Assessment of Medication Adherence. Results: Antipsychotic polypharmacy was common (65.2%), and LAI use was high (60.2%; LAI alone 17.1%, oral + LAI 43.1%). Most patients received SGAs only (82.9%), whereas 17.1% used an FGA + SGA combination. Compared with APM, APP was associated with older age, longer illness duration, and more hospitalizations, as well as greater symptom burden and clinical severity (higher m-PANSS and BCASS scores and higher CGI-S) and poorer functioning (lower GAF). Clozapine was prescribed to 21.5% of patients, predominantly within APP. Conclusion: In patients with schizophrenia receiving care at CMHCs in Türkiye, prescription is characterized by frequent APP and substantial LAI use, concentrated among individuals with more severe and chronic illness profiles. These real-world patterns may diverge from guideline-recommended pathways and underscore the need for individualized, evidence-based strategies to optimize outcomes in CMHC populations. Cite this article as: Asan Ö, Yıldız M, Kenar ANİ, et al. Antipsychotic treatment patterns and associated clinical characteristics in schizophrenia: a multicenter study from community mental health centers in Türkiye. Neuropsychiatr Invest. 2026, 64, 0002, doi: 10.5152/NI.2026.26002.
- 27 March 2026
- Published by SAGE Publications in International Journal of Social Psychiatry
Public Knowledge, Stigma, and Discrimination Toward Schizophrenia: Results From a National Survey in Türkiye
Purpose: In light of the limited and predominantly regional evidence on public stigma toward schizophrenia in Türkiye, this study aimed to address the lack of nationally representative data by investigating public perceptions of schizophrenia, levels of knowledge, and attitudes toward social distance and related factors in a large, nationally representative sample from Türkiye. In doing so, the research questions were explicitly derived from this gap, focusing on how education, socioeconomic status, gender, and familiarity with mental illness are associated with knowledge and social distance. Methods: A total of 1,030 adults were surveyed between 4 and 26 September 2019. Data were collected through Computer-Assisted Personal Interviewing (CAPI) conducted by 32 trained interviewers who had received sensitivity training on mental illness before fieldwork. The questionnaire was developed by an expert academic committee with extensive experience in stigma research. Data analysis included frequency distributions, cross-tabulations, and significance testing. Results: Overall, 63.7% of participants recognized schizophrenia as a brain disorder, although 27% still attributed it to character weakness, reflecting ongoing stigma. Approximately 40% acknowledged psychosocial factors (e.g. poverty) in the etiology of schizophrenia, 54% recognized its association with cannabis use, and 39.4% considered individuals with schizophrenia to be dangerous. More negative beliefs were observed among lower socioeconomic and educational groups, whereas participants with personal or familial experience of mental illness demonstrated greater knowledge and less stigmatizing attitudes. Conclusion: This study provides the first nationally representative evidence on public knowledge, stigma, and discriminatory attitudes toward schizophrenia in Türkiye. While a majority of respondents endorsed biomedical explanations, substantial proportions continued to express stigmatizing beliefs and social distance, particularly among individuals with lower socioeconomic status and educational attainment. These findings highlight persistent structural and informational inequalities shaping public stigma and underscore the need for targeted, culturally sensitive educational and anti-stigma interventions to promote social inclusion and reduce discrimination.
- 27 March 2026
- Published by SAGE Publications in International Journal of Social Psychiatry
Public Knowledge, Stigma, and Discrimination Toward Schizophrenia: Results From a National Survey in Türkiye
Purpose: In light of the limited and predominantly regional evidence on public stigma toward schizophrenia in Türkiye, this study aimed to address the lack of nationally representative data by investigating public perceptions of schizophrenia, levels of knowledge, and attitudes toward social distance and related factors in a large, nationally representative sample from Türkiye. In doing so, the research questions were explicitly derived from this gap, focusing on how education, socioeconomic status, gender, and familiarity with mental illness are associated with knowledge and social distance. Methods: A total of 1,030 adults were surveyed between 4 and 26 September 2019. Data were collected through Computer-Assisted Personal Interviewing (CAPI) conducted by 32 trained interviewers who had received sensitivity training on mental illness before fieldwork. The questionnaire was developed by an expert academic committee with extensive experience in stigma research. Data analysis included frequency distributions, cross-tabulations, and significance testing. Results: Overall, 63.7% of participants recognized schizophrenia as a brain disorder, although 27% still attributed it to character weakness, reflecting ongoing stigma. Approximately 40% acknowledged psychosocial factors (e.g. poverty) in the etiology of schizophrenia, 54% recognized its association with cannabis use, and 39.4% considered individuals with schizophrenia to be dangerous. More negative beliefs were observed among lower socioeconomic and educational groups, whereas participants with personal or familial experience of mental illness demonstrated greater knowledge and less stigmatizing attitudes. Conclusion: This study provides the first nationally representative evidence on public knowledge, stigma, and discriminatory attitudes toward schizophrenia in Türkiye. While a majority of respondents endorsed biomedical explanations, substantial proportions continued to express stigmatizing beliefs and social distance, particularly among individuals with lower socioeconomic status and educational attainment. These findings highlight persistent structural and informational inequalities shaping public stigma and underscore the need for targeted, culturally sensitive educational and anti-stigma interventions to promote social inclusion and reduce discrimination.
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 43 (4) , 22-36
Metabolic Syndrome with Different Antipsychotics: A Multicentre Cross-Sectional Study
High prevalence of Metabolic Syndrome (MS) and related metabolic disturbances in patients with schizophrenia and bipolar affective disorder have been in main focus of interest in recent years since the introduction of second-generation antipsychotics. This study aims to examine these questions: 1) Is there a relation between antipsychotic treatment and MS prevalence? 2) Which antipsychotic users have higher MS prevalence? 3) Do patients on antipsychotic polytherapy have higher rates of MS than patients on antipsychotic monotherapy? 4) Which metabolic parameters are considerably disturbed on which antipsychotic users? Methods: 242 patients with schizophrenia, schizoaffective disorder and bipolar disorder without any other psychiatric comorbidity according to DSM-IV and using the same antipsychotic(s) and/or mood stabilizers at least for the last 6 months were included in the final assessment. Results: The sample was divided into 7 drug groups. The MS prevalence was highest in the combined antipsychotic (AA) group (48.1%) according to ATP III criteria. According to IDF criteria clozapine (C) group had the highest MS prevalence (74%). Conclusions: When metabolic parameters were evaluated overall, metabolic risk with antipsychotics was found to be highest in the clozapine group, followed by the combined AP group. Olanzapine and risperidone have intermediate risk while zuclopentixole has the lowest. Psychopharmacology Bulletin. 2010;43(4):22–36.
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 43 (4) , 22-36
Metabolic Syndrome with Different Antipsychotics: A Multicentre Cross-Sectional Study
High prevalence of Metabolic Syndrome (MS) and related metabolic disturbances in patients with schizophrenia and bipolar affective disorder have been in main focus of interest in recent years since the introduction of second-generation antipsychotics. This study aims to examine these questions: 1) Is there a relation between antipsychotic treatment and MS prevalence? 2) Which antipsychotic users have higher MS prevalence? 3) Do patients on antipsychotic polytherapy have higher rates of MS than patients on antipsychotic monotherapy? 4) Which metabolic parameters are considerably disturbed on which antipsychotic users? Methods: 242 patients with schizophrenia, schizoaffective disorder and bipolar disorder without any other psychiatric comorbidity according to DSM-IV and using the same antipsychotic(s) and/or mood stabilizers at least for the last 6 months were included in the final assessment. Results: The sample was divided into 7 drug groups. The MS prevalence was highest in the combined antipsychotic (AA) group (48.1%) according to ATP III criteria. According to IDF criteria clozapine (C) group had the highest MS prevalence (74%). Conclusions: When metabolic parameters were evaluated overall, metabolic risk with antipsychotics was found to be highest in the clozapine group, followed by the combined AP group. Olanzapine and risperidone have intermediate risk while zuclopentixole has the lowest. Psychopharmacology Bulletin. 2010;43(4):22–36.
- Open Access
- 18 December 2024
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 34 (4) , 320-327
Global Assessment of Medication Adherence: Correlational Analyses of a Brief Tool for Evaluating Medication Adherence in Patients with Severe Mental Disorders
Assessment of medication adherence of patients with severe mental disorders is an important aspect of long-term treatment. There is a need for a brief and practical tool to assess medication adherence. This study investigates the clinical, functional, and validational correlations of a short and easy-to-use tool. Global Assessment of Medication Adherence (GAMA) was prepared as a single item with 5 severity degrees, from complete adherence (1 point) to complete nonadherence (5 points). The scale was applied to patients with severe mental illnesses receiving outpatient and inpatient treatment. The GAMA scores were compared with psychopathology, clinical severity, insight, and functionality scale scores. While the validity analyses were tested with face, convergent, and criterion validity, interrater reliability was used for the reliability analysis. Data from 70 outpatients and 14 inpatients were examined. In the analyses performed for convergent validity, a positive correlation was found between GAMA scores and psychopathology (r=0.646, P < .001), and clinical severity (r = 0.692, P < .001), and a significant negative correlation was found between GAMA scores and insight (r = -0.793, P < .001), and functionality (r = -0.740, P < .001). There was a significant difference in the GAMA scores of 14 patients assessed during hospitalization and discharge. A high positive correlation was found between the GAMA measurements of the psychiatrist and the nurse at admission and discharge. This study shows that the GAMA has sufficient psychometric properties for assessing medication adherence. Due to its brevity, simplicity, and validity, the scale is appropriate for use in routine clinical practice and research.
- 18 December 2024
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 34 (4) , 320-327
Open AccessGlobal Assessment of Medication Adherence: Correlational Analyses of a Brief Tool for Evaluating Medication Adherence in Patients with Severe Mental Disorders
Assessment of medication adherence of patients with severe mental disorders is an important aspect of long-term treatment. There is a need for a brief and practical tool to assess medication adherence. This study investigates the clinical, functional, and validational correlations of a short and easy-to-use tool. Global Assessment of Medication Adherence (GAMA) was prepared as a single item with 5 severity degrees, from complete adherence (1 point) to complete nonadherence (5 points). The scale was applied to patients with severe mental illnesses receiving outpatient and inpatient treatment. The GAMA scores were compared with psychopathology, clinical severity, insight, and functionality scale scores. While the validity analyses were tested with face, convergent, and criterion validity, interrater reliability was used for the reliability analysis. Data from 70 outpatients and 14 inpatients were examined. In the analyses performed for convergent validity, a positive correlation was found between GAMA scores and psychopathology (r=0.646, P < .001), and clinical severity (r = 0.692, P < .001), and a significant negative correlation was found between GAMA scores and insight (r = -0.793, P < .001), and functionality (r = -0.740, P < .001). There was a significant difference in the GAMA scores of 14 patients assessed during hospitalization and discharge. A high positive correlation was found between the GAMA measurements of the psychiatrist and the nurse at admission and discharge. This study shows that the GAMA has sufficient psychometric properties for assessing medication adherence. Due to its brevity, simplicity, and validity, the scale is appropriate for use in routine clinical practice and research.
- 1 April 2024
- Published by Galenos Yayinevi in Gazi Medical Journal
- Vol. 35 (2) , 121-131
Development of the COVID-19 Stigma Scale: Validity and Reliability Study
- 1 April 2024
- Published by Galenos Yayinevi in Gazi Medical Journal
- Vol. 35 (2) , 121-131
Development of the COVID-19 Stigma Scale: Validity and Reliability Study
- 15 July 2022
- Published by Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
- Vol. 17 (2) , 112-122
Voxel Based Morphometric Analysis of Regional Gray Matter Alterations Related with Duration of Illness, Number of Psychotic Episodes, Lifetime Antipsychotics Use in Patient with Schizophrenia
Objective: Schizophrenia is known to be quite a heterogeneous disorder in terms of etiological factors, clinical features and, treatment response. Changes in gray matter areas with structural imaging studies seem to be a reflection of this diversity. The relationship of duration of illness, active psychosis periods, and antipsychotic treatment with structural changes in the brain has not been clarified yet. The aim of our study is to investigate the effects of the disease and disease-related processes (duration of illness, antipsychotic treatment, number of the psychotic episodes) on the brain structures. Material and Methods: Thirty three schizophrenic patients and 35 age, gender and education matched healthy volunteers participated in our study. Life-time antipsychotic exposure determined for the patients and inverted dose/year unit over equivalent chlorpromazine doses. Magnetic resonance images were acquired with a 3 Tesla-powered imaging unit. By using Statistical Parametric Mapping 8, images were compared with voxel-based morphometry (VBM) analysis. Independent samples t-test for statistical evaluation based on the data characteristics were used. By using the general linear model (GLM) age, gender, and total brain volume were included as confounding factors in the analyze matrix in VBM. In GLM, t-test was used to compare two groups and to investigate disease process-related GM changes, multiple regression analysis were applied. In VBM, p values of less than 0.001 and areas with a minimum expected number of voxels per cluster of 50 are required. Results: Compared to controls, patients showed decrements in gray matter density in the right middle and inferior temporal gyrus, bilateral middle frontal gyrus, left cingulate gyrus, left precentral gyrus, left supramarginal gyrus. Nevertheless, patients showed increased GM density in the right uncus, left caudate, and left posterior cingulate cortex as compared to controls. In the patient group, duration of illness was negatively associated with GM density in the left precentral gyrus and left postcentral gyrus. The lifetime exposure to antipsychotics correlated negatively and positively with gray matter density in, respectively; left inferior frontal gyrus and right precuneus. The number of psychotic episodes was positively associated with GM density in the left medial frontal gyrus, right precentral gyrus and left paracentral lobule whereas negatively in the uvula (cerebellum). Conclusion: It can be said that GM deficits in schizophrenic patients are prominent in frontal and temporal areas. Besides illness duration, antipsychotic treatment, and number of psychotic episodes seem to be associated with changes in brain GM. Further studies are needed to clarify the increase in the limbic lobe GM density.
- 15 July 2022
- Published by Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
- Vol. 17 (2) , 112-122
Voxel Based Morphometric Analysis of Regional Gray Matter Alterations Related with Duration of Illness, Number of Psychotic Episodes, Lifetime Antipsychotics Use in Patient with Schizophrenia
Objective: Schizophrenia is known to be quite a heterogeneous disorder in terms of etiological factors, clinical features and, treatment response. Changes in gray matter areas with structural imaging studies seem to be a reflection of this diversity. The relationship of duration of illness, active psychosis periods, and antipsychotic treatment with structural changes in the brain has not been clarified yet. The aim of our study is to investigate the effects of the disease and disease-related processes (duration of illness, antipsychotic treatment, number of the psychotic episodes) on the brain structures. Material and Methods: Thirty three schizophrenic patients and 35 age, gender and education matched healthy volunteers participated in our study. Life-time antipsychotic exposure determined for the patients and inverted dose/year unit over equivalent chlorpromazine doses. Magnetic resonance images were acquired with a 3 Tesla-powered imaging unit. By using Statistical Parametric Mapping 8, images were compared with voxel-based morphometry (VBM) analysis. Independent samples t-test for statistical evaluation based on the data characteristics were used. By using the general linear model (GLM) age, gender, and total brain volume were included as confounding factors in the analyze matrix in VBM. In GLM, t-test was used to compare two groups and to investigate disease process-related GM changes, multiple regression analysis were applied. In VBM, p values of less than 0.001 and areas with a minimum expected number of voxels per cluster of 50 are required. Results: Compared to controls, patients showed decrements in gray matter density in the right middle and inferior temporal gyrus, bilateral middle frontal gyrus, left cingulate gyrus, left precentral gyrus, left supramarginal gyrus. Nevertheless, patients showed increased GM density in the right uncus, left caudate, and left posterior cingulate cortex as compared to controls. In the patient group, duration of illness was negatively associated with GM density in the left precentral gyrus and left postcentral gyrus. The lifetime exposure to antipsychotics correlated negatively and positively with gray matter density in, respectively; left inferior frontal gyrus and right precuneus. The number of psychotic episodes was positively associated with GM density in the left medial frontal gyrus, right precentral gyrus and left paracentral lobule whereas negatively in the uvula (cerebellum). Conclusion: It can be said that GM deficits in schizophrenic patients are prominent in frontal and temporal areas. Besides illness duration, antipsychotic treatment, and number of psychotic episodes seem to be associated with changes in brain GM. Further studies are needed to clarify the increase in the limbic lobe GM density.
- 1 March 2022
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 59 (1) , 14-20
Brief Clinical Assessment Scale for Schizophrenia (BCASS): Development, Validity, and Reliability Study
Introduction: The instruments used for the clinical assessment of schizophrenia and other psychotic disorders are not commonly administered in routine clinical practice since their application takes a long time. This study aims to develop a short, comprehensive, and easy-to-apply scale and to examine its psychometric properties. Methods: A 14-item scale was prepared by adding two items inquiring about obsessions and memory difficulties to the items taken from Positive and Negative Syndrome Scale (PANSS) covering the diagnostic criteria for schizophrenia and schizoaffective disorder. The items were rated on a 4-point scale reflecting their effect on daily functioning as 1. not present, 2. mild problems, 3. moderate problems, 4. severe problems. The scale was administered together with other concordant scales to the patients with schizophrenia and schizoaffective disorder. The construct validity of the scale was analyzed by explanatory factor analysis, the concurrent validity was examined through correlations of the scale scores with those of comparable scales, and criterion validity was evaluated by the sensitivity to the change in psychopathology. For reliability, internal consistency coefficient and interrater reliability were assessed. Results: Data from a total of 120 patients were analyzed. The internal consistency coefficient of the scale was calculated as 0.89. Exploratory factor analysis yielded a 4-factor solution which accounted for 74.47% of the total variance of the scale scores. The first factor (psychosis) explained 43.49% of the total variance, the second factor (negative/cognitive impairment) explained 14.53%, the third factor (emotional distress) explained 11.19%, and the fourth factor (disorganization) explained 5.34% of the total variance. Significant correlations were found between the scale's total score and the PANSS (=0.78), Clinical General Impression-Severity (CGI-S) (r=0.81), and Global Assessment of Functioning (GAF) scores (r=-0.77). Interrater reliability was strong (ICC=0.89), and the sensitivity to the change in psychopathology was significant (Cohen d=2.68). Conclusion: The scale demonstrated adequate psychometric properties in terms of reliability, validity, and dimensionality that justify its use in routine clinical practice.
- 1 March 2022
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 59 (1) , 14-20
Brief Clinical Assessment Scale for Schizophrenia (BCASS): Development, Validity, and Reliability Study
Introduction: The instruments used for the clinical assessment of schizophrenia and other psychotic disorders are not commonly administered in routine clinical practice since their application takes a long time. This study aims to develop a short, comprehensive, and easy-to-apply scale and to examine its psychometric properties. Methods: A 14-item scale was prepared by adding two items inquiring about obsessions and memory difficulties to the items taken from Positive and Negative Syndrome Scale (PANSS) covering the diagnostic criteria for schizophrenia and schizoaffective disorder. The items were rated on a 4-point scale reflecting their effect on daily functioning as 1. not present, 2. mild problems, 3. moderate problems, 4. severe problems. The scale was administered together with other concordant scales to the patients with schizophrenia and schizoaffective disorder. The construct validity of the scale was analyzed by explanatory factor analysis, the concurrent validity was examined through correlations of the scale scores with those of comparable scales, and criterion validity was evaluated by the sensitivity to the change in psychopathology. For reliability, internal consistency coefficient and interrater reliability were assessed. Results: Data from a total of 120 patients were analyzed. The internal consistency coefficient of the scale was calculated as 0.89. Exploratory factor analysis yielded a 4-factor solution which accounted for 74.47% of the total variance of the scale scores. The first factor (psychosis) explained 43.49% of the total variance, the second factor (negative/cognitive impairment) explained 14.53%, the third factor (emotional distress) explained 11.19%, and the fourth factor (disorganization) explained 5.34% of the total variance. Significant correlations were found between the scale's total score and the PANSS (=0.78), Clinical General Impression-Severity (CGI-S) (r=0.81), and Global Assessment of Functioning (GAF) scores (r=-0.77). Interrater reliability was strong (ICC=0.89), and the sensitivity to the change in psychopathology was significant (Cohen d=2.68). Conclusion: The scale demonstrated adequate psychometric properties in terms of reliability, validity, and dimensionality that justify its use in routine clinical practice.
- 1 January 2022
- Published by Turkish Association of Nervous and Mental Health in Turkish Journal of Psychiatry
- Vol. 33 (2) , 146-148
RETHINKING THE COST OF ANTIPSYCHOTIC TREATMENT: THE AVERAGE COST OF THE DRUGS USED IN TURKEY IN 2020
Dear Editor, The costs of antipsychotic drugs (APDs) used in the treatment of mental disorders with psychosis are mentioned in treatment guidelines (APA 2021, NICE 2014). While the American Psychiatric Association guideline states that every specialist should make decisions according to the rules and conditions of their country and their region, the National Institute of Health and Clinical Excellence guideline emphasizes that drug costs must be taken into consideration in the treatment process. Classical or first-generation antipsychotic drugs (FAPDs) are relatively cheaper in terms of sales prices compared to atypical or second-generation antipsychotic drugs (SAPDs) with a slightly different effect mechanism. The price difference between the two drug groups can be so large that sometimes it may be necessary to consider whether the cost of a second-generation drug is worth its benefit. While deciding on the use of first-generation or second-generation drugs, a multifaceted assessment should be made, such as the patient's level of compliance with the treatment, the possibility of occurrence of side effects, the possible effects of these side effects on body health and treatment compliance, and whether or not the costs are covered. The most important criterion that determines the choice of medication for psychiatrists is of course the multi-dimensional benefit/harm ratio that the drug used will reveal in the long term. We think that in our country, which, in terms of economic indicators is not in a strong position as an importer of pharmaceutical raw materials from abroad, APDs' cost calculation should be considered because drug costs constitute an important part of the direct treatment costs of psychotic disorders in developing countries such as Turkey (Yıldız and Cerit 2006). We calculated the unit (mg) price based on the box prices of the APDs in use in 2020, thinking that it might work when calculating the cost of the illness using APDs as the main component of the treatment and calculated the annual average drug costs with the daily average dosage. Although the daily treatment dose varies with the stage of the illness and the individual characteristics of the patient, the average doses recommended for maintenance treatment were used here (Öztürk and Ulusahin 2018). The daily and annual cost calculations based on the assumption that the average maintenance treatment dose was used with the unit price obtained from (Drug Prices 2020) the drugs in the Turkish pharmaceutical market in September 2020 are shown in Table 1. A similar study was done in 2005 (Yıldız 2005). The purpose of this article is to redetermine the average costs of APDs in the Turkish pharmaceutical market every 15 years and to bring them to the attention of experts in terms of cost-effectiveness studies. When the costs in 2005 are examined, it is seen that the annual costs of the FAPDs were around 450 TRY, and the annual cost of oral preparations of SAPDs was 2,500 TRY (5 times the first generation). In 2005, there was only one depot of SAPD (risperidon consta) that allowed intramuscular (IM) administration, and its average annual cost was 5,400 TRY, 3 times more than the tablet form (1,700 TRY). In 2005, when the price of risperidone consta, which was the first second-generation depot APD, were compared with the prices of the first-generation depot drugs (fluphenazine = 380 TRY, flupentixol = 876 TRY, zuclopentixol = 730 TRY), the cost difference was 6-14 times. This almost-10-fold difference between the cost of the first and second generation APDs was remarkable. It is seen that this difference (risperidone consta = 10,807 TRY, fluphenazine = 916 TRY, flupentixol = 1,007 TRY, zuclopenthixol = 2,372 TRY, and haloperidol deconate 237 TRY) did not change in 2020. In 2020, the average RETHINKING THE COST OF ANTIPSYCHOTIC TREATMENT: THE AVERAGE COST OF THE DRUGS USED IN TURKEY IN 2020 2 Türk Psikiyatri Dergisi 2 Turkish Journal of Psychiatry Letter to the Editor 146 147 annual cost of oral use preparations of FAPDs is 925 TRY, while the average annual cost of oral forms of SAPDs is 2,580 TRY. The 5-fold difference observed in 2005 between the first and second-generation ones of the oral APDs decreased to 2.5 times in 2020. It is clear that while the difference between the cost of oral use of first- and second-generation drugs was halved in 2020, the difference between the costs of depot preparations applied with IM did not change. In 2005, the average dollar rate was 1.34 TRY, and in 2020 it was 7.02 TRY (Republic of Turkey Central Bank Exchange Rates, 2021). It is understood that the 5-fold increase in dollar exchange rate is not reflected in all drug prices in the same way. For example, there was a 3 to 4-fold increase in the prices of haloperidol, chlorpromazine, fluphenazine, trifluperazine and zuclopenthixol, while a less than two-fold increase in pimozide, flupenthixol, sulpiride, amisulpride and quetiapine and a decrease in the prices of clozapine, olanzapine, ziprasidone and risperidone in the tablet form. There is also a two-fold increase in the price of risperidone consta. The fluctuations in drug prices in 2005 and 2020 are shown in Table 2 in 500, 1,000, 2,000, 3,000 and 5,000 TRY brackets. It is noteworthy that while some drugs have moved into an upper price bracket in terms of annual costs, some have fallen into a lower price bracket. The prices of the second generation long-acting (depot) antipsycotic drugs (LA-APDs), which were not available in the Turkish pharmaceutical market in 2005, are quite high compared to others. In 2020, the annual cost of all of them, including risperidone consta, is over 10 thousand TRY. It is understood that the underlying reason for such price increase is the fact that the drug is wanted/sought after/new/marketed rather than the dollar exchange rate. For example, while there was a certain increase in the price of FAPDs, the increase in...
- 1 January 2022
- Published by Turkish Association of Nervous and Mental Health in Turkish Journal of Psychiatry
- Vol. 33 (2) , 146-148
RETHINKING THE COST OF ANTIPSYCHOTIC TREATMENT: THE AVERAGE COST OF THE DRUGS USED IN TURKEY IN 2020
Dear Editor, The costs of antipsychotic drugs (APDs) used in the treatment of mental disorders with psychosis are mentioned in treatment guidelines (APA 2021, NICE 2014). While the American Psychiatric Association guideline states that every specialist should make decisions according to the rules and conditions of their country and their region, the National Institute of Health and Clinical Excellence guideline emphasizes that drug costs must be taken into consideration in the treatment process. Classical or first-generation antipsychotic drugs (FAPDs) are relatively cheaper in terms of sales prices compared to atypical or second-generation antipsychotic drugs (SAPDs) with a slightly different effect mechanism. The price difference between the two drug groups can be so large that sometimes it may be necessary to consider whether the cost of a second-generation drug is worth its benefit. While deciding on the use of first-generation or second-generation drugs, a multifaceted assessment should be made, such as the patient's level of compliance with the treatment, the possibility of occurrence of side effects, the possible effects of these side effects on body health and treatment compliance, and whether or not the costs are covered. The most important criterion that determines the choice of medication for psychiatrists is of course the multi-dimensional benefit/harm ratio that the drug used will reveal in the long term. We think that in our country, which, in terms of economic indicators is not in a strong position as an importer of pharmaceutical raw materials from abroad, APDs' cost calculation should be considered because drug costs constitute an important part of the direct treatment costs of psychotic disorders in developing countries such as Turkey (Yıldız and Cerit 2006). We calculated the unit (mg) price based on the box prices of the APDs in use in 2020, thinking that it might work when calculating the cost of the illness using APDs as the main component of the treatment and calculated the annual average drug costs with the daily average dosage. Although the daily treatment dose varies with the stage of the illness and the individual characteristics of the patient, the average doses recommended for maintenance treatment were used here (Öztürk and Ulusahin 2018). The daily and annual cost calculations based on the assumption that the average maintenance treatment dose was used with the unit price obtained from (Drug Prices 2020) the drugs in the Turkish pharmaceutical market in September 2020 are shown in Table 1. A similar study was done in 2005 (Yıldız 2005). The purpose of this article is to redetermine the average costs of APDs in the Turkish pharmaceutical market every 15 years and to bring them to the attention of experts in terms of cost-effectiveness studies. When the costs in 2005 are examined, it is seen that the annual costs of the FAPDs were around 450 TRY, and the annual cost of oral preparations of SAPDs was 2,500 TRY (5 times the first generation). In 2005, there was only one depot of SAPD (risperidon consta) that allowed intramuscular (IM) administration, and its average annual cost was 5,400 TRY, 3 times more than the tablet form (1,700 TRY). In 2005, when the price of risperidone consta, which was the first second-generation depot APD, were compared with the prices of the first-generation depot drugs (fluphenazine = 380 TRY, flupentixol = 876 TRY, zuclopentixol = 730 TRY), the cost difference was 6-14 times. This almost-10-fold difference between the cost of the first and second generation APDs was remarkable. It is seen that this difference (risperidone consta = 10,807 TRY, fluphenazine = 916 TRY, flupentixol = 1,007 TRY, zuclopenthixol = 2,372 TRY, and haloperidol deconate 237 TRY) did not change in 2020. In 2020, the average RETHINKING THE COST OF ANTIPSYCHOTIC TREATMENT: THE AVERAGE COST OF THE DRUGS USED IN TURKEY IN 2020 2 Türk Psikiyatri Dergisi 2 Turkish Journal of Psychiatry Letter to the Editor 146 147 annual cost of oral use preparations of FAPDs is 925 TRY, while the average annual cost of oral forms of SAPDs is 2,580 TRY. The 5-fold difference observed in 2005 between the first and second-generation ones of the oral APDs decreased to 2.5 times in 2020. It is clear that while the difference between the cost of oral use of first- and second-generation drugs was halved in 2020, the difference between the costs of depot preparations applied with IM did not change. In 2005, the average dollar rate was 1.34 TRY, and in 2020 it was 7.02 TRY (Republic of Turkey Central Bank Exchange Rates, 2021). It is understood that the 5-fold increase in dollar exchange rate is not reflected in all drug prices in the same way. For example, there was a 3 to 4-fold increase in the prices of haloperidol, chlorpromazine, fluphenazine, trifluperazine and zuclopenthixol, while a less than two-fold increase in pimozide, flupenthixol, sulpiride, amisulpride and quetiapine and a decrease in the prices of clozapine, olanzapine, ziprasidone and risperidone in the tablet form. There is also a two-fold increase in the price of risperidone consta. The fluctuations in drug prices in 2005 and 2020 are shown in Table 2 in 500, 1,000, 2,000, 3,000 and 5,000 TRY brackets. It is noteworthy that while some drugs have moved into an upper price bracket in terms of annual costs, some have fallen into a lower price bracket. The prices of the second generation long-acting (depot) antipsycotic drugs (LA-APDs), which were not available in the Turkish pharmaceutical market in 2005, are quite high compared to others. In 2020, the annual cost of all of them, including risperidone consta, is over 10 thousand TRY. It is understood that the underlying reason for such price increase is the fact that the drug is wanted/sought after/new/marketed rather than the dollar exchange rate. For example, while there was a certain increase in the price of FAPDs, the increase in...
- Open Access
- 25 December 2021
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 18 (12) , 1180-1187
Caregiver Burden in Schizophrenia and Autism Spectrum Disorders: A Comparative Study
Objective There is no study comparing schizophrenia and autism spectrum disorders (ASD) in terms of caregiver burden. This study aims to compare the caregiver burden among family members of the patients with schizophrenia and ASD and investigate the predictive factors.Methods A cross-sectional study with the family members living with and/or providing care to their patients was carried out. A sociodemographic form, the Beck Depression Inventory, the Self-Stigma Inventory for Families, and the Zarit Caregiver Burden Scale were utilized. Regression analyses were conducted to determine the predictive factors for higher burden.Results Caregiver burden in ASD was significantly higher than in schizophrenia. Regression analysis showed that the predictors of high caregiver burden were the need for self-care (OR=3.6), self-destructive behaviors (OR=3.4), self-stigma (OR=1.1), depression (OR=1.1), and level of income (OR=1.0) for all family members. When the diagnosis was removed from the equation, the factors determining the high burden did not change.Conclusion This study suggests that characteristics of the illness are stronger predictors than family members’ characteristics in explaining high caregiver burden for both illnesses. Psychological, social, and economic supports should be provided for families to help alleviate their caregiving burden.
- 25 December 2021
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 18 (12) , 1180-1187
Open AccessCaregiver Burden in Schizophrenia and Autism Spectrum Disorders: A Comparative Study
Objective There is no study comparing schizophrenia and autism spectrum disorders (ASD) in terms of caregiver burden. This study aims to compare the caregiver burden among family members of the patients with schizophrenia and ASD and investigate the predictive factors.Methods A cross-sectional study with the family members living with and/or providing care to their patients was carried out. A sociodemographic form, the Beck Depression Inventory, the Self-Stigma Inventory for Families, and the Zarit Caregiver Burden Scale were utilized. Regression analyses were conducted to determine the predictive factors for higher burden.Results Caregiver burden in ASD was significantly higher than in schizophrenia. Regression analysis showed that the predictors of high caregiver burden were the need for self-care (OR=3.6), self-destructive behaviors (OR=3.4), self-stigma (OR=1.1), depression (OR=1.1), and level of income (OR=1.0) for all family members. When the diagnosis was removed from the equation, the factors determining the high burden did not change.Conclusion This study suggests that characteristics of the illness are stronger predictors than family members’ characteristics in explaining high caregiver burden for both illnesses. Psychological, social, and economic supports should be provided for families to help alleviate their caregiving burden.
- 1 November 2021
- Published by Kocaeli Universitesi Saglik Bilimleri Dergisi in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 7 (3) , 228-234
Şizofreni Hastalarında Destekli İşe Yerleştirim: Üç Yıllık İzlem Sonucunun Değerlendirmesi
Amaç: Şizofreni hastalığı olan bireylerin hastalık belirtileri ve toplumsal etkenler nedeniyle iş yaşamına katılım oranı düşüktür. Oysaki hastaların iş yaşamında olmasının iyileştirici özelliği bilinmektedir. Hastaların işe yerleştirimi için değişik hizmet modelleri geliştirilmiştir. Burada olgu yöneticiliği uygulamasıyla işe yerleştirilen bir grup şizofreni hastasının üç yıllık iş yaşamı sonuçları sunulacaktır. Yöntem: Olgu yöneticiliği uygulamasıyla destekli işe yerleştirim hizmetleri için belirlenmiş ilkeler çerçevesinde hastaların niteliklerine uygun konumlarda toplumla bütünleşik olan işe yerleştirme çalışması yapıldı. İş yeri ile klinik hizmetler arasında eşgüdüm sağlanarak çalışan hastalara bireyselleştirilmiş destek sağlandı. Bu hizmetler kapsamında engelli ya da normal kadrodan işe yerleştirilmiş 12 şizofreni hastasının üç yıllık izlem verileri incelendi. Katılımcıların klinik ve toplumsal işlevsellikleri destekli işe yerleştirim hizmetlerinden önce ve sonra ölçüldü. Sonuçlar parametrik olmayan testlerden olan Wilcoxon Testi ile değerlendirildi.Bulgular: Çalışmaya alınan hastaların 3’ü (%25) normal kadrodan, 9’u (%75) engelli kadrosundan işe başladı. Devlet sektöründe memur/hizmetli kadrosunda 7 hasta (%58), özel sektörde 5 hasta (%42) işe başladı. Destekli işe yerleştirim hizmetleri sunulan katılımcıların 10’nu (%83) 36 ay boyunca işine devam etti. Destekli işe yerleştirim sonrasında klinik ve toplumsal işlevsellik alanlarındaki ölçeklerden alınan puanlarda başlangıç ölçümlerine göre anlamlı fark saptandı.Sonuç: Olgu yöneticiliği uygulamasıyla yürütülen destekli işe yerleştirim hizmetlerinin şizofreni hastalığı olan bireylerin işe yerleşmesinde, işi sürdürmesinde, hastalık belirtilerinin azalmasında, toplumsal işlevselliklerinin artmasında ve aile yükünün azalmasında önemli katkıları olacağı söylenebilir.
- 1 November 2021
- Published by Kocaeli Universitesi Saglik Bilimleri Dergisi in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 7 (3) , 228-234
Şizofreni Hastalarında Destekli İşe Yerleştirim: Üç Yıllık İzlem Sonucunun Değerlendirmesi
Amaç: Şizofreni hastalığı olan bireylerin hastalık belirtileri ve toplumsal etkenler nedeniyle iş yaşamına katılım oranı düşüktür. Oysaki hastaların iş yaşamında olmasının iyileştirici özelliği bilinmektedir. Hastaların işe yerleştirimi için değişik hizmet modelleri geliştirilmiştir. Burada olgu yöneticiliği uygulamasıyla işe yerleştirilen bir grup şizofreni hastasının üç yıllık iş yaşamı sonuçları sunulacaktır. Yöntem: Olgu yöneticiliği uygulamasıyla destekli işe yerleştirim hizmetleri için belirlenmiş ilkeler çerçevesinde hastaların niteliklerine uygun konumlarda toplumla bütünleşik olan işe yerleştirme çalışması yapıldı. İş yeri ile klinik hizmetler arasında eşgüdüm sağlanarak çalışan hastalara bireyselleştirilmiş destek sağlandı. Bu hizmetler kapsamında engelli ya da normal kadrodan işe yerleştirilmiş 12 şizofreni hastasının üç yıllık izlem verileri incelendi. Katılımcıların klinik ve toplumsal işlevsellikleri destekli işe yerleştirim hizmetlerinden önce ve sonra ölçüldü. Sonuçlar parametrik olmayan testlerden olan Wilcoxon Testi ile değerlendirildi.Bulgular: Çalışmaya alınan hastaların 3’ü (%25) normal kadrodan, 9’u (%75) engelli kadrosundan işe başladı. Devlet sektöründe memur/hizmetli kadrosunda 7 hasta (%58), özel sektörde 5 hasta (%42) işe başladı. Destekli işe yerleştirim hizmetleri sunulan katılımcıların 10’nu (%83) 36 ay boyunca işine devam etti. Destekli işe yerleştirim sonrasında klinik ve toplumsal işlevsellik alanlarındaki ölçeklerden alınan puanlarda başlangıç ölçümlerine göre anlamlı fark saptandı.Sonuç: Olgu yöneticiliği uygulamasıyla yürütülen destekli işe yerleştirim hizmetlerinin şizofreni hastalığı olan bireylerin işe yerleşmesinde, işi sürdürmesinde, hastalık belirtilerinin azalmasında, toplumsal işlevselliklerinin artmasında ve aile yükünün azalmasında önemli katkıları olacağı söylenebilir.